Sotera Health (NASDAQ:SHC) Given New $20.00 Price Target at Citigroup

Sotera Health (NASDAQ:SHC) had its price objective increased by Citigroup from $18.00 to $20.00 in a research note published on Wednesday, Benzinga reports. Citigroup currently has a buy rating on the stock.

SHC has been the topic of several other reports. Barclays boosted their price objective on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a research report on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.50.

Sotera Health Stock Up 4.5 %

NASDAQ:SHC opened at $16.11 on Wednesday. The stock has a market cap of $4.56 billion, a price-to-earnings ratio of 115.07 and a beta of 2.08. The company has a current ratio of 2.93, a quick ratio of 2.59 and a debt-to-equity ratio of 5.46. The stock has a 50-day moving average price of $15.96 and a two-hundred day moving average price of $13.69. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.44.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. Sotera Health’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.18 earnings per share. As a group, equities analysts expect that Sotera Health will post 0.64 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now owns 49,215,301 shares in the company, valued at $739,705,974.03. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 55.12% of the company’s stock.

Hedge Funds Weigh In On Sotera Health

Several hedge funds and other institutional investors have recently made changes to their positions in the company. CWM LLC lifted its stake in Sotera Health by 86.1% in the second quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after acquiring an additional 993 shares during the last quarter. GAMMA Investing LLC lifted its stake in Sotera Health by 125.0% in the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock valued at $50,000 after purchasing an additional 1,660 shares during the last quarter. Point72 DIFC Ltd grew its holdings in Sotera Health by 556.6% during the second quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock worth $78,000 after purchasing an additional 5,544 shares during the period. Capital Performance Advisors LLP acquired a new position in Sotera Health during the third quarter worth approximately $91,000. Finally, Acadian Asset Management LLC raised its stake in Sotera Health by 728.0% in the second quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock valued at $111,000 after buying an additional 8,248 shares during the period. 91.03% of the stock is owned by institutional investors.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.